Data as of Jul 25, 2026 · Based on 2,718,867 AI responses across 9,511 prompts · See how Parse measures this
Azafarosazafaros.com · Low evidenceAzafaros is a biotechnology company developing nizubaglustat, an orally available azasugar for treating central nervous system disorders by interfering with glycosphingolipid metabolism. The compound uses a unique dual mode of action to address key disease pathways in rare genetic conditions.
Parse Score